
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
CORRECTION article
Front. Pharmacol. , 02 September 2021
Sec. Translational Pharmacology
Volume 12 - 2021 | https://doi.org/10.3389/fphar.2021.758192
This article is a correction to:
Dose Dependent Antimicrobial Cellular Cytotoxicity—Implications for ex vivo Diagnostics
A Corrigendum on
Dose Dependent Antimicrobial Cellular Cytotoxicity—Implications for ex vivo Diagnostics
by Copaescu, A., Choshi, P., Pedretti, S., Mouhtouris, E., Peter, J., and Trubiano, J. A. (2021). Front. Pharmacol. 12:640012. doi: 10.3389/fphar.2021.640012
In the original article, we mistakenly omitted a statement from the Funding section. The statement reads as follows: “JP receives financial support from National Institutes of Health, award K43TW011178-02; the EDCTP2 programme supported by the European Union, grant number TMA2017SF-1981 and the South African National Research Foundation (NRF). PC receives a PhD fellowship from the Fogarty HATTP program, funded by the National Institutes of Health, award D43 TW010559-01”.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
Keywords: delayed hypersensitivity reaction, drug allergy, severe cutaneous adverse reaction, t-cell, enzyme link immunospot, cytotoxicity, flow cytoametry, lactate dehydrogenase
Citation: Copaescu A, Choshi P, Pedretti S, Mouhtouris E, Peter J and Trubiano JA (2021) Corrigendum: Dose Dependent Antimicrobial Cellular Cytotoxicity—Implications for ex vivo Diagnostics. Front. Pharmacol. 12:758192. doi: 10.3389/fphar.2021.758192
Received: 13 August 2021; Accepted: 18 August 2021;
Published: 02 September 2021.
Approved by:
Frontiers Editorial Office, Frontiers Media SA, SwitzerlandCopyright © 2021 Copaescu, Choshi, Pedretti, Mouhtouris, Peter and Trubiano. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ana Copaescu, YW5hLmNvcGFlc2N1QGdtYWlsLmNvbQ==
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.